	US 12,435,116 B2
	Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
Clarence Hurt, Los Altos, CA (US); and Luis Soares, Ormond Beach, FL (US)
Filed by Clarence Hurt, Los Altos, CA (US); and Luis Soares, Ormond Beach, FL (US)
Filed on Oct. 16, 2020, as Appl. No. 17/073,138.
Claims priority of provisional application 62/915,680, filed on Oct. 16, 2019.
Prior Publication US 2022/0064249 A1, Mar. 3, 2022
Int. Cl. C07K 14/62 (2006.01); A61K 31/519 (2006.01); A61K 38/00 (2006.01); A61K 47/64 (2017.01)

CPC C07K 14/62 (2013.01) [A61K 31/519 (2013.01); A61K 47/64 (2017.08); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)]

9 Claims

1. A compound having a structure of Formula (I):

X1-[X2-(X3)m]n (I)

or a pharmaceutically acceptable salt, solvate, hydrate, isomer, or tautomer thereof: wherein:

m is 1, 2, or 3;

n is 1, 2, or 3;

X1 is a wild type human insulin;

X2 is a glucuronide or dipeptide cleavable linker; and

X3 is Pevonedistat.